-
公开(公告)号：EP2068851A4
公开(公告)日：2010-07-14
申请号：EP07871111
申请日：2007-10-02
CPC分类号： A61K31/325 , C12Q1/34 , G01N33/92 , G01N2500/02
-
公开(公告)号：EP0833899A4
公开(公告)日：2000-06-28
申请号：EP96918507
申请日：1996-06-12
IPC分类号： C12N15/00 , A61K31/12 , A61P43/00 , C07C45/45 , C07C49/227 , C07C57/03 , C07C233/09 , C07C327/22 , C07F9/54 , C12N9/80 , C12N9/99 , C12P7/64 , C12N9/78 , A61K38/46 , C12N9/14
CPC分类号： C12P7/6418 , C07C45/45 , C07C49/227 , C07C57/03 , C07C233/09 , C07C327/22 , C07F9/5407 , C12N9/80 , C12N9/99
摘要： The soporific activity of cis-9,10-octadecenoamide and other soporific fatty acid primary amides is neutralized by hydrolysis in the presence of cis-9,10-octadecenoamidase. Hydrolysis of cis-9,10-octadecenoamide leads to the formation of oleic acid, a compound without soporific activity. Inhibitors of cis-9,10-octadecenoamidase are disclosed to block this activity.
摘要翻译： 在顺-9,10-十八碳烯酰胺酶存在下，通过水解中和顺-9,10-十八碳烯酰胺和其他可溶性脂肪酸伯酰胺的催化活性。 顺-9,10-十八碳烯酰胺的水解导致形成油酸，这是一种无催化活性的化合物。 公开了顺-9,10-十八碳烯酰胺酶抑制剂阻断这种活性。
-
公开(公告)号：EP1419237A4
公开(公告)日：2005-12-21
申请号：EP02750363
申请日：2002-07-30
发明人： CRAVATT BENJAMIN F
IPC分类号： A61K49/00 , A61P25/00 , C12N9/16 , C12N9/80 , C12N15/55 , C12N15/85 , A01K67/027 , A61K31/00 , C12N5/10 , G01N33/50 , G01N33/68
CPC分类号： C12N15/8509 , A01K67/0276 , A01K2217/072 , A01K2217/075 , A01K2227/105 , A01K2267/03 , A01K2267/0356 , A61K49/0008 , C12N9/16 , C12N9/80 , C12N2830/008
摘要： The invention relates to animal model for studying behavior related to fatty acid amide and hydrolysis of fatty acid amide. The invention provides transgenic animals in which the protein fatty acid amide hydrolase is not expressed, and methods of using such animals.
-
公开(公告)号：EP1461621A4
公开(公告)日：2005-11-23
申请号：EP02792303
申请日：2002-11-25
发明人： CRAVATT BENJAMIN F , LIU YONGSHENG , JESSANI NADIN
IPC分类号： C12N9/64 , C12Q1/34 , G01N33/574
CPC分类号： C12N9/6424 , C12Q1/34 , G01N33/57496 , G01N2333/914
摘要： Methods and compositions are provided for evaluating cellular status related to neoplasia. Affinity based probes, particularly having fluorophosphonates as a reactive functionality, are employed that react with a family of enzymes having a common catalytic activity, particularly serine/threonine hydrolases. The probe(s) are combined with the cell components and resulting conjugates are characterized, where the profile of reaction indicates cellular status. A novel serine/threonine hydrolase enzyme is provided.
-
5.发明公开METHODS AND COMPOSITIONS RELATED TO TARGETING MONOACYLGLYCEROL LIPASE 审中-公开方法和组合物相关MONOACYLGLYCEROLLIPASE靶向
公开(公告)号：EP2373315A4
公开(公告)日：2012-06-27
申请号：EP09826412
申请日：2009-11-10
IPC分类号： A61K31/496 , A61P23/00
CPC分类号： A61K31/00 , A61K31/496 , C12N15/1137 , C12N2310/14 , C12N2310/531
-
公开(公告)号：EP1769071A4
公开(公告)日：2008-12-31
申请号：EP05788798
申请日：2005-06-01
CPC分类号： G01N33/6803 , C12Q1/37 , G01N33/573 , G01N33/6818 , G01N33/6842 , G01N2333/96486
摘要： Activity-based compositions for analyzing metalloproteases are disclosed, where the compositions include a chemical compound including a hydroxamate moiety and a benzophenone moiety. Methods for synthesizing these compounds are also disclosed, as well as methods of using them for determining the bioactivity of a compositions comprising active compounds toward a metalloproteases and for determining the potency of an inhibitor against a metalloprotease.
-
公开(公告)号：EP2800565A4
公开(公告)日：2015-04-29
申请号：EP13733636
申请日：2013-01-07
发明人： CISAR JUSTIN S , GRICE CHERYL A , JONES TODD K , NIPHAKIS MICAH J , CHANG JAE WON , LUM KENNETH M , CRAVATT BENJAMIN F
IPC分类号： A61K31/27 , A61K31/325 , C07C269/00 , C07C271/00 , C07C271/62 , C07D203/20
CPC分类号： C07D295/205 , C07C271/10 , C07C271/12 , C07D205/04 , C07D207/09 , C07D207/14 , C07D213/38 , C07D213/40 , C07D213/55 , C07D215/42 , C07D215/46 , C07D231/12 , C07D231/16 , C07D231/56 , C07D241/04 , C07D261/08 , C07D263/32 , C07D271/06 , C07D295/26 , C07D307/79 , C07D317/46 , C07D317/58 , C07D401/04 , C07D401/10 , C07D403/10 , C07D405/14 , C07D407/06 , C07D413/06 , C07D413/10 , C07D471/04 , C07D471/10 , C07D487/04 , C07D491/107
摘要： This disclosure provides compounds and compositions which may be modulators of MAGL and/or ABHD6 and their use as medicinal agents, processes for their preparation, and pharmaceutical compositions that include disclosed compounds as at least one active agent. The disclosure also provides for method of treating a patient in need thereof, where the patient is suffering from indications such as pain, solid tumor cancer and/or obesity comprising administering a disclosed compound or composition.
-
-
公开(公告)号：EP1039902A4
公开(公告)日：2002-07-17
申请号：EP98960363
申请日：1998-11-24
IPC分类号： C07D295/18 , A61K31/16 , A61K31/201 , A61K31/231 , A61K31/27 , A61K31/40 , C07C47/21 , C07C49/227 , C07C57/12 , C07C69/58 , C07C233/09 , C07C233/10 , C07C233/11 , C07C233/20 , C07C233/49 , C07C235/06 , C07C235/28 , C07C235/76 , C07C237/22 , C07C243/30 , C07C245/14 , C07C259/06 , C07C271/10 , C07C275/20 , C07C323/60 , C07C327/32 , C07D207/00 , A01N43/36 , C07C59/00 , C07C233/00 , C07D295/00
CPC分类号： C07C233/09
摘要： Oleamide is an endogenous fatty acid primary amide that possesses sleep-inducing properties in animals and has been shown to effect seratonergic systems and block gap junction communication in a structurally specific manner. Certain agents can serve both as an oleamide agonist and as an inhibitor of fatty acid amide hydrolase. Fatty acid amide hydrolase is responsible for the rapid inactivation of oleamide in vivo. The structural features of oleamide required for inhibition of gap junction-mediated chemical and electrical transmission in rat glial cells are defined. Effective inhibitors fall into two classes of fatty acid primary amides of which oleamide and arachidonamide are the prototypical members. Of these two, oleamide constitutes the most effective and its structural requirements for inhibition of the gap junction are well defined. It requires a chain length of 16-24 carbons of which 16-18 carbons appears optimal, a polarized terminal carbonyl group capable of accepting but not necessarily donating a hydrogen bond, a DELTA 9 cis double bond, and a hydrophobic methyl terminus. Within these constraints, a range of modifications are possible, many of which may with enhanced in vivo properties.
-
公开(公告)号：EP0970195A4
公开(公告)日：2001-12-05
申请号：EP97948210
申请日：1997-11-04
IPC分类号： C12N15/00 , A61K31/12 , A61K38/46 , A61P25/00 , A61P25/20 , A61P43/00 , C07C45/45 , C07C49/227 , C07C57/03 , C07C233/09 , C07C327/22 , C07F9/54 , C12N9/80 , C12N9/99 , C12N15/09 , C12P7/64 , C12Q1/34 , C12N9/78 , C12N9/14
CPC分类号： C07C45/45 , C07C49/227 , C07C57/03 , C07C233/09 , C07C327/22 , C07F9/5407 , C12N9/80 , C12N9/99 , C12P7/6418
摘要： The soporific activity of cis-9,10-octadecenoamide and other soporific fatty-acid primary amides is neutralized by hydrolysis in the presence of fatty-acid amide hydrolase (FAAH). Hydrolysis of cis-9,10-octadecenoamide by FAAH leads to the formation of oleic acid, a compound without soporific activity. FAAH has been isolated and the gene encoding FAAH has been cloned, sequenced, and used to express recombinant FAAH. Inhibitors of FAAH are disclosed to block the hydrolase activity.
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.016 秒)
